Yarrow Bioscience, Inc. reported a net loss of $9.7 million for the third quarter of 2026, driven by $10.7 million in operating expenses. Following a merger, the company significantly strengthened its balance sheet, ending the period with $268.9 million in cash and cash equivalents compared to $100.0 million at the end of 2025.
Yarrow Bioscience reported third quarter 2026 financial results, ending the period with $268.9 million in cash following a $172.5 million public offering. The company is currently enrolling patients in its Phase 2a/2b DIRECTION-GD trial for YB-101, with topline data expected in the second half of 2027.
“We made significant progress in the third quarter, including dosing our first patient in the Phase 2a portion of the DIRECTION-GD trial and strengthening our balance sheet through the completion of our merger and subsequent public offering. The financing extends our expected cash runway into 2030 and positions us to advance YB-101 in Graves’ disease and prepare for our next steps in thyroid eye disease.”
Rebecca V. Frey, PharmD, President and Chief Executive Officer
Yarrow Bioscience entered into an underwriting agreement to sell 5,769,231 shares of common stock at $26.00 per share. The underwriters fully exercised their option to purchase an additional 865,384 shares, bringing the total expected net proceeds to approximately $161.8 million after expenses.
Value
$172M
Counterparty
Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC